Is Exosome Therapy FDA-Approved?

This is the question every clinician who is offered exosome material should be able to answer before it reaches a patient: is any of this FDA-approved? The answer is short, and it has not changed. It also gets misstated constantly, in both directions. Some sellers imply approval that does not exist. Some clinicians assume that because a product is not approved, it is therefore banned. Neither is accurate.

This article states the FDA's actual position, explains why exosomes fall where they do, and lays out what the position means for how you source, describe, and offer exosome material in your practice. It is educational and written for practicing clinicians. It is not legal advice, and regulations and enforcement change. Verify against current FDA guidance and your own regulatory counsel for your specific situation.

What the FDA Has Said, and When

The FDA's position is not new and it is not ambiguous. In a public safety communication issued in December 2019, the agency stated plainly that "there are currently no FDA-approved exosome products," and it has repeated and reinforced that position since. The FDA has also warned that patients and clinicians have been exposed to unapproved products marketed for serious conditions, and that these products carry real risk of harm.

Two things about that statement matter for a practice:

• It is a statement about approval, not about legality of the material itself. A substance can exist, be sold, and be handled lawfully in certain contexts while still not being approved as a therapy.
• It is about therapeutic use. The FDA's concern attaches to claims and uses that present exosomes as a treatment for disease or a replacement for an approved therapy.

The agency has not been quiet on this since 2019. Enforcement has continued and, by several accounts, intensified: the FDA has issued warning letters to firms marketing exosome products, and the Department of Justice has brought enforcement actions in the regenerative medicine space. The Federal Trade Commission has separately pursued deceptive advertising claims. The direction of travel is toward more scrutiny, not less.

Why Exosomes Are Regulated as Biological Products

Under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act, a product intended to treat, cure, mitigate, or prevent disease is regulated as a drug or biological product. That framing, not the biology of exosomes specifically, is what determines the regulatory category. If a product is offered to treat a condition, it is being held out as a therapeutic, and therapeutics require premarket approval.

For cellular and tissue-based products, the FDA applies the framework in 21 CFR Part 1271. Products that meet all four criteria in 1271.10(a) (minimally manipulated, same surgical procedure, homologous use, no systemic effect) are regulated more lightly under Section 361. Products that fail any one of those criteria fall under Section 351 and require premarket approval. Most exosome material offered for clinical use does not fit the narrow Section 361 criteria, which is why the FDA treats it as a Section 351 biological product. For a deeper walk through that framework, see our guide to 21 CFR 1271.

The "Research Use Only" and Cosmetic Workarounds

Two labels show up constantly in this market, and both are frequently misunderstood.

"Research use only" (RUO)

An RUO label is a real regulatory category. It signals that a product is intended for laboratory research and not for administration to humans. What it does not do is launder a clinical use. If material labeled RUO is in fact administered to patients, the label offers no protection: the use is what the FDA regulates, not the sticker on the vial. An RUO label is not a permission slip, and it is not a substitute for the IND or BLA a therapeutic use would require.

"Cosmetic" or "topical" positioning

Some products are marketed as cosmetics or skincare to sidestep the therapeutic framing. That can be legitimate for genuinely cosmetic products making cosmetic claims. It stops being a workaround the moment the product is described, implied, or used as a treatment for a disease, condition, or injury. The marketing claim and the intended use are what draw the regulatory line, and a clinic that advertises a cosmetic-positioned product as a therapy has crossed it regardless of the label.

What This Means for Your Practice

If there is no approved exosome therapy, the practical question for a clinician is not "which one is approved," because none is. It is "how do I handle this material and describe it in a way that is honest, defensible, and consistent with how the FDA views it." That comes down to three things: what the material is, what you say about it, and what you can document.

What the material is

Characterization is factual. You can describe the source, the type, the processing, and the documentation that accompanies a batch. That is not a therapeutic claim.

What you say about it

Any statement that the material treats, cures, or prevents a disease is a therapeutic claim, and a therapeutic claim about an unapproved product is the fastest way into a warning letter. This is where most regenerative medicine marketing violations originate.

What you can document

Supplier documentation, certificates of analysis, donor screening records, and chain of custody are what let you answer a regulator, an insurer, or a patient's question. If you cannot produce it, you cannot defend the use.

What You Can and Cannot Say

The distinction is between characterization (what the material is) and therapeutic claims (what the material does). Characterization is factual. Therapeutic claims about an unapproved product are not permitted.

You can say	You cannot say
"Exosome material derived from [source]"	"Exosomes treat [disease or condition]"
"Wharton's jelly-derived MSC exosomes"	"Exosome therapy for [condition]"
"Research use only material"	"FDA-approved exosome treatment"
"Independent COA included"	"Clinically proven to reduce inflammation"
"Documentation available on request"	"Proven to promote healing or regeneration"

The FTC applies a parallel standard for advertising: claims must be supported by competent and reliable scientific evidence. Practitioner experience and patient testimonials, on their own, do not meet that bar. If you say a study shows something, you need the study, and it needs to be the kind of evidence the claim implies.

How to Evaluate What You Are Offered

Since no exosome product is approved, due diligence is the only protection a clinic has. When a supplier offers you exosome material, ask:

1. What exactly is this, and how is it characterized? Source, type, and processing, in writing.
2. What documentation accompanies the batch? A current certificate of analysis, ideally from an independent lab, and donor screening records.
3. What is this intended for? If the answer is a therapeutic use, understand that no approved pathway exists and get your own regulatory counsel involved.
4. What claims are on the marketing material? If the supplier's own copy promises treatment outcomes, that tells you how they view the regulatory line, and it should raise your concern.
5. Can you trace this specific lot? Chain of custody and lot-level records, or you cannot defend it later.

Our companion piece, How to Evaluate an Exosome Supplier, turns these into a full checklist you can hand to your team.

Practical Steps for Your Practice

1. Stop using the word "approved." No exosome product is FDA-approved. Do not let it appear on a website, a brochure, a consent form, or a staff script.
2. Audit every marketing claim. Replace "treats" and "cures" with characterization language, or remove the claim entirely.
3. Keep the material and the claim consistent. If a product is positioned as research use only or cosmetic, it cannot also be advertised as a therapy.
4. Request and file documentation for every batch. COA, donor screening, and lot records, retained as your 21 CFR 1271 obligations require.
5. Train your staff on what they can and cannot say to patients, because a front-desk sentence can create the claim you were trying to avoid.
6. Get regulatory counsel involved before any use that could be characterized as therapeutic. This is not a judgment call to make alone.
7. Watch your state as well. Federal law is the floor. State medical boards and clinic statutes layer on top. See our state compliance guide.

The Bottom Line

No exosome product is FDA-approved for therapeutic use, and the FDA has said so repeatedly since 2019. Exosome products intended as treatments are regulated as biological products and require premarket approval through a pathway that no marketed exosome product has completed. RUO and cosmetic labels describe a market, not an authorization, and they do not make a therapeutic use lawful.

That does not put a clinician out of business. It sets the terms: describe what the material is, never what it does, document every batch, and get counsel before you cross from handling material into treating a patient. The practices that run into trouble are rarely the ones that studied the framework. They are the ones that assumed the framework did not apply, or took a supplier's word that "everything is compliant" without asking what that meant.

Verify. Characterize. Document. If you cannot verify it, do not claim it. If you cannot document it, do not do it.